Last reviewed · How we verify
NCT04800731
Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19
trial testing observation no intervention in Lymphopenia in 227 participants. Completed in 30 June 2022.
30 June 2022
Quick facts
| Lead sponsor | Universitair Ziekenhuis Brussel |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 227 |
| Start date | 30 June 2021 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- observation no intervention
Conditions studied
- Lymphopenia — all drugs for Lymphopenia →
- Covid19 — all drugs for Covid19 →
- Older People — all drugs for Older People →
Sponsor
Universitair Ziekenhuis Brussel — full company profile →
Who can join
70 and older, any sex, with Lymphopenia or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Lymphopenia is reported to be associated with the severity of disease progression in COVID-19. Low lymphocyte count is also associated with increasing age. No study has yet investigated the effects of lymphopenia in this disease on the outcome in elderly people. Objectives: To assess the outcome of lymphopenia in elderly patients having COVID-19 and its usefulness as prognostic factor in elderly people. Methods: Retrospective cohort study. Clinical data (medical history, comorbidities, treatments, geriatric syndromes) and biological parameters will be collected from 100 hospitalized geriatric COVID-19 patients (\> 70 yrs.) (Group 1) and 100 hospitalized geriatric patients (\> 70 yrs.) presenting with acute infection other than COVID-19 (Group 2) and will be compared according to the presence/absence of lymphopenia. A third Group (3) will be studied to assess the influence of comorbidities on lymphopenia consisting of healthy aged elderly (\> 70 yrs.).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04800731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphopenia
Currently open trials in the same condition.
- NCT06181656 — Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemor · recruiting
Other Universitair Ziekenhuis Brussel trials
Trials by the same sponsor.
- NCT07536230 — Deep Learning Framework for Continuous Depth of Anesthesia Forecasting · not yet recruiting
- NCT07533968 — The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in I · NA · not yet recruiting
- NCT07289984 — Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders and · NA · not yet recruiting
- NCT06923813 — Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calo · NA · recruiting
- NCT07401004 — Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04800731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitair Ziekenhuis Brussel
- Last refreshed: 31 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04800731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing